Study Name:
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment (Navigator)
Targeted Disease(s):
COPD
Purpose of Study:
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
Study Dates:
June 30, 2026 - June 11, 2028
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Multi-Center Trial
Funding Source:
We are a venture backed company
Sponsors:
Expedition Therapeutics
Contact:
Gabriela Sanchez
Phone: 619-361-5429
Email: gabriela.sanchez@expeditiontx.com
ClinicalTrails.gov Identifier:
NCT07684820
This study does not have a dedicated study website. For additional information about the study, please visit the study listing on ClinicalTrials.gov.
